The nearly 500,000 participants in this study were categorized in one of the following five groups: low HbA1c (mean 5.1), normoglycemic (mean 5.6), prediabetes (mean 6.2), known diabetes (mean 7.0), or unknown diabetes (mean 7.5). Prediabetes was associated with a 54% increased (adjusted) risk for vascular dementia, while diabetes carried a nearly 3-fold higher risk. Prediabetes and diabetes had a similar increase in risk for cognitive decline (42% and 39%, respectively), while diabetes had a nearly 2-fold higher risk for both all-cause and Alzheimer’s dementias.
Antihypertensive medication use appeared to account for some of the excess risk found between prediabetes and vascular dementia. The authors suggest rather than an adverse effect of medication, this is more likely an indicator of hypertension that had been untreated for far too long, again emphasizing the importance of optimizing both blood pressure and glucose/insulin regulation early, rather than waiting for overt disease to progress.
There also was an apparent benefit in the low HbA1c group; individuals in this group had greater hippocampal volume and lower white matter hyperintensity (WMH) volume compared with normoglycemic individuals. Hippocampal atrophy is a consequence of hyperglycemia linked to cognitive decline and memory loss, while WMH volume is a tentative indicator of neurological decline. In sharp contrast, hippocampal volume declined approximately 80mm3 among diabetics compared to those with normoglycemia, in contrast to the 12mm3 increase found among those in the low HbA1c group. Given the nearly 2-fold increase in cardiovascular disease risk among prediabetics (in a separate analysis of this same cohort), the advantage to achieving healthy glucose control could not be clearer.